stockrowLivaNova PLC
LIVN Healthcare Medical Devices
LivaNova PLC’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 10.7% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +27.0%
- Free cash flow
- −31.0%
- Total debt
- −31.2%
Quarter to September 2026, against a year earlier
Follow LIVN
Alert me
LivaNova PLC (LIVN) Revenue
LivaNova PLC's revenue for fiscal 2025 was $1.4B, up 10.7% from $1.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.5B. Over the past ten years it has ranged from $291.6M (fiscal 2015) to $1.4B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. LivaNova PLC ranks 24th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.4B | 10.74% |
| FY2024 | $1.3B | 8.66% |
| FY2023 | $1.2B | 12.89% |
| FY2022 | $1.0B | (1.31%) |
| FY2021 | $1.0B | 10.82% |
| FY2020 | $934.2M | (13.83%) |
| FY2019 | $1.1B | (2.06%) |
| FY2018 | $1.1B | 9.35% |
| FY2017 | $1.0B | 4.91% |
| FY2016 | $964.9M | 230.93% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $393.1M | 0.66% |
| Jun 2026 | $390.6M | 7.82% |
| Mar 2026 | $362.3M | 0.37% |
| Dec 2025 | $360.9M | 0.89% |
| 45 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BRKR Bruker Corporation compare | $3.5B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| ITGR Integer Holdings Corporation compare | $1.8B |
| LIVN LivaNova PLC | $1.5B |
| HAE Haemonetics Corporation compare | $1.4B |
| NEOG Neogen Corporation compare | $884.0M |
| IRTC iRhythm Holdings, Inc. compare | $854.0M |
| TXG 10x Genomics compare | $616.9M |
| AXGN AxoGen, Inc. compare | $266.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LIVN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement